Managers / Q3 2023 · view latest →
Northpond Ventures, LLC
CIK 0001911245 · 7500 OLD GEORGETOWN ROAD, SUITE 800, BETHESDA, MD, 20814 · 240-800-1200
Summary
Northpond Ventures, LLC reported $35M in U.S.-listed holdings across 3 positions for Q3 2023.
The portfolio is heavily concentrated: VIGL alone accounts for 65.4% of reported value.
Compared with Q2 2023, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 70.5% · $24M
- Other · 29.5% · $10M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PHENOMEX INC | SOLD OUT | −5.39M | 0 | −$3M | $0 |
| VIGLVIGIL NEUROSCIENCE INC | HELD | +0 | 4.21M | −$17M | $23M |
| TELESIS BIO INC | HELD | +0 | 9.84M | −$5M | $10M |
| CADLCANDEL THERAPEUTICS INC | HELD | +0 | 1.94M | −$657,973 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | VIGLVIGIL NEUROSCIENCE INChistory → | COM | 65.40% | $23M | 4.21M |
| 2 | TELESIS BIO INC | COM | 29.47% | $10M | 9.84M |
| 3 | CADLCANDEL THERAPEUTICS INChistory → | COM | 5.13% | $2M | 1.94M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 3 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $55M | 4 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $103M | 4 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $21M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $35M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $60M | 4 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $175M | 5 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $184M | 5 | Feb 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $143M | 5 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $105M | 5 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $286M | 4 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.